Study summary

Mosunetuzumab plus lenalidomide beat rituximab plus lenalidomide at relapse

CELESTIMO trial · 478 people, phase 3 · Topline results September 2026 (Roche)

What was tested

Mosunetuzumab, a bispecific antibody already approved for later-line follicular lymphoma, plus lenalidomide, against rituximab plus lenalidomide, for relapsed or refractory follicular lymphoma.

What they found

• Met its main goal at an interim analysis, with significantly longer progression-free survival.
• Survival data were not yet mature.
• Full data are to be presented at a medical meeting and shared with regulators.

What it means

Sets up a third T-cell-engager combination competing for second-line treatment.